nach oben

Urolithiasis

Erschienen in:

26.11.2018 | Invited Review

Empiric therapy for kidney stones

verfasst von: David S. Goldfarb

Erschienen in: Urolithiasis | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Careful phenotyping of patients to classify those with kidney stones has a long and important history in revealing the chemical basis for stone formation. Advances in our genetic understanding of kidney stones will lead to incredible insights regarding the pathophysiology of this common disorder. At this time, both evaluation of urine chemistry and genotyping of patients are extremely useful in the setting of a university and research-based kidney stone clinic. For much of the world, in a more clinically focused setting, these techniques are neither available nor absolutely necessary. Careful implementation of an empiric prescription based on stone composition would have an important effect to reduce stone recurrence in the world’s many stone formers. Increased fluid intake, generic dietary manipulations, and prescription of potassium citrate and thiazides are all appropriate empiric therapies for people with calcium and uric acid kidney stones.

Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R (2013) Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol 28(10):1923–1942PubMedPubMedCentralCrossRef

Goldfarb DS, Fischer ME, Keich Y, Goldberg J (2005) A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 67(3):1053–1061PubMedCrossRef

Milose JC, Kaufman SR, Hollenbeck BK, Wolf JS Jr, Hollingsworth JM (2014) Prevalence of 24-hour urine collection in high risk stone formers. J Urol 191(2):376–380PubMedCrossRef

Pak CY, Britton F, Peterson R, Ward D, Northcutt C, Breslau NA, McGuire J, Sakhaee K, Bush S, Nicar M, Norman DA, Peters P (1980) Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 69(1):19–30PubMedCrossRef

Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR, American Urological A (2014) Medical management of kidney stones: AUA guideline. J Urol 192(2):316–324PubMedCrossRef

Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petrik A, Turk C (2015) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol 67(4):750–763PubMedCrossRef

Goldfarb DS (2013) Kidney stones and the risk of coronary heart disease. Am J Kidney Dis 62(6):1039–1041PubMedCrossRef

Rule AD, Lieske JC, Li X, Melton LJ 3rd, Krambeck AE, Bergstralh EJ (2014) The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol 25(12):2878–2886PubMedPubMedCentralCrossRef

Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ (1998) Body size and risk of kidney stones. J Am Soc Nephrol 9(9):1645–1652PubMed

10.

Taylor EN, Stampfer MJ, Curhan GC (2005) Obesity, weight gain, and the risk of kidney stones. JAMA 293(4):455–462PubMedCrossRef

11.

Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC, Consensus Conference Group (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29(6):715–734PubMedPubMedCentralCrossRef

12.

Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A (1996) Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 155(3):839–843PubMedCrossRef

13.

Xu C, Zhang C, Wang XL, Liu TZ, Zeng XT, Li S, Duan XW (2015) Self-fluid management in prevention of kidney stones: A PRISMA-compliant systematic review and dose-response meta-analysis of observational studies. Medicine (Baltimore) 94(27):e1042CrossRef

14.

Mass AY, Goldfarb DS, Shah O (2014) Taxi cab syndrome: a review of the extensive genitourinary pathology experienced by taxi cab drivers and what we can do to help. Rev Urol 16(3):99–104PubMedPubMedCentral

15.

Kim CW, Chang Y, Zhao D, Cainzos-Achirica M, Ryu S, Jung HS, Yun KE, Choi Y, Ahn J, Zhang Y, Rampal S, Baek Y, Lima JA, Shin H, Guallar E, Cho J, Sung E (2015) Sleep duration, sleep quality, and markers of subclinical arterial disease in healthy men and women. Arterioscler Thromb Vasc Biol 35(10):2238–2245PubMedCrossRef

16.

Policastro LJ, Saggi SJ, Goldfarb DS, Weiss JP (2017) Personalized intervention in monogenic stone formers. J Urol. https://doi.org/10.1016/j.juro.2017.09.143 PubMedPubMedCentralCrossRef

17.

Ljunghall S, Danielson BG, Fellstrom B, Holmgren K, Johansson G, Wikstrom B (1985) Family history of renal stones in recurrent stone patients. Br J Urol 57(4):370–374PubMedCrossRef

18.

Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1997) Family history and risk of kidney stones. J Am Soc Nephrol 8(10):1568–1573PubMed

19.

Vezzoli G, Soldati L, Gambaro G (2008) Update on primary hypercalciuria from a genetic perspective. JUrol 179(5):1676–1682

20.

Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjornsson G, Haraldsdottir E, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Masson G, Holm H, Gudbjartsson DF, Thorsteinsdottir U, Indridason OS, Palsson R, Stefansson K (2015) Common and rare variants associated with kidney stones and biochemical traits. Nat Commun 6:7975PubMedPubMedCentralCrossRef

21.

Vezzoli G, Terranegra A, Arcidiacono T, Soldati L (2011) Genetics and calcium nephrolithiasis. Kidney Int 80(6):587–593PubMedCrossRef

22.

Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, Fisher B, Spaneas L, Porath JD, Braun DA, Wassner AJ, Nelson CP, Tasic V, Sayer JA, Hildebrandt F (2015) Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26(3):543–551PubMedCrossRef

23.

Braun DA, Lawson JA, Gee HY, Halbritter J, Shril S, Tan W, Stein D, Wassner AJ, Ferguson MA, Gucev Z, Fisher B, Spaneas L, Varner J, Sayer JA, Milosevic D, Baum M, Tasic V, Hildebrandt F (2016) Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol 11(4):664–672PubMedPubMedCentralCrossRef

24.

Martin-Higueras C, Torres A, Salido E (2017) Molecular therapy of primary hyperoxaluria. J Inherit Metab Dis 40(4):481–489PubMedCrossRef

25.

Dindo M, Conter C, Oppici E, Ceccarelli V, Marinucci L, Cellini B (2018) Molecular basis of primary hyperoxaluria: clues to innovative treatments. Urolithiasis. https://doi.org/10.1007/s00240-018-1089-z PubMedCrossRef

26.

Chillaron J, Font-Llitjos M, Fort J, Zorzano A, Goldfarb DS, Nunes V, Palacin M (2010) Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 6(7):424–434PubMedCrossRef

27.

Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D, group VXs (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2(7):527–538PubMedCrossRef

28.

Hsi RS, Sanford T, Goldfarb DS, Stoller ML (2017) The role of the 24-hour urine collection in the prevention of kidney stone recurrence. J Urol 197(4):1084–1089PubMedCrossRef

29.

Parks JH, Coward M, Coe FL (1997) Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 51(3):894–900PubMedCrossRef

30.

Kocvara R, Plasgura P, Petrik A, Louzensky G, Bartonickova K, Dvoracek J (1999) A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 84(4):393–398PubMedCrossRef

31.

Lingeman J, Mardis H, Kahnoski R, Goldfarb DS, Lacy S, Grasso M, Scheinman SJ, Parks JH, Asplin JR, Coe FL (1998) Medical reduction of stone risk in a network of treatment centers compared to a research clinic. J Urol 160(5):1629–1634PubMedCrossRef

32.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59(6):2290–2298PubMedCrossRef

33.

Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A (2002) Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346(2):77–84PubMedCrossRef

34.

Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1993) A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328(12):833–838PubMedCrossRef

35.

Taylor EN, Curhan GC (2008) Determinants of 24-hour urinary oxalate excretion. Clin J Am Soc Nephrol 3(5):1453–1460PubMedPubMedCentralCrossRef

36.

Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N (1997) A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336(16):1117–1124PubMedCrossRef

37.

Taylor EN, Fung TT, Curhan GC (2009) DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 20(10):2253–2259PubMedPubMedCentralCrossRef

38.

Taylor EN, Stampfer MJ, Mount DB, Curhan GC (2010) DASH-style diet and 24-hour urine composition. Clin J Amer Soc Nephrol 5(12):2315–2322CrossRef

39.

Goldfarb DS (2012) A woman with recurrent calcium phosphate kidney stones. Clin J Am Soc Nephrol 7(7):1172–1178PubMedCrossRef

40.

Asplin JR, Bauer KA, Kinder J, Muller G, Coe BJ, Parks JH, Coe FL (2003) Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 63(2):662–669PubMedCrossRef

41.

Jehle S, Hulter HN, Krapf R (2012) Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 98(1):207–217PubMedCrossRef

42.

Huen SC, Goldfarb DS (2007) Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. J Urol 177(4):1238–1243PubMedCrossRef

43.

Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13(9):679–685PubMedCrossRef

44.

Wasnich R, Davis J, Ross P, Vogel J (1990) Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ 301(6764):1303–1305PubMedPubMedCentralCrossRef

45.

Wright JT Jr, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH, Group ACR (2009) ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 169(9):832–842PubMedPubMedCentralCrossRef

46.

Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21(3):257–264PubMedCrossRef

47.

Ticinesi A, Guerra A, Allegri F, Nouvenne A, Cervellin G, Maggio M, Lauretani F, Borghi L, Meschi T (2018) Determinants of calcium and oxalate excretion in subjects with calcium nephrolithiasis: the role of metabolic syndrome traits. J Nephrol 31(3):395–403PubMedCrossRef

48.

Nicar MJ, Peterson R, Pak CY (1984) Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol 131(3):430–433PubMedCrossRef

49.

Arrabal-Polo MA, Arias-Santiago S, de Haro-Munoz T, Lopez-Ruiz A, Orgaz-Molina J, Gonzalez-Torres S, Zuluaga-Gomez A, Arrabal-Martin M (2013) Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. Urology 81(4):731–737PubMedCrossRef

50.

Prochaska M, Taylor E, Vaidya A, Curhan G (2017) Low bone density and bisphosphonate use and the risk of kidney stones. Clin J Am Soc Nephrol 12(8):1284–1290PubMedPubMedCentralCrossRef

51.

Trinchieri A, Montanari E (2017) Prevalence of renal uric acid stones in the adult. Urolithiasis 45(6):553–562PubMedCrossRef

52.

Mehta TH, Goldfarb DS (2012) Uric acid stones and hyperuricosuria. Adv Chronic Kidney Dis 19(6):413–418PubMedCrossRef

53.

Maalouf NM, Cameron MA, Moe OW, Sakhaee K (2004) Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 13(2):181–189PubMedCrossRef

54.

Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K (2004) The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65(2):386–392PubMedCrossRef

55.

Ware EB, Riehle E, Smith JA, Zhao W, Turner ST, Kardia SL, Lieske JC (2015) SLC2A9 genotype is associated with SLC2A9 gene expression and urinary uric acid concentration. PLoS One 10(7):e0128593PubMedPubMedCentralCrossRef

56.

Canales BK, Smith JA, Weiner ID, Ware EB, Zhao W, Kardia SLR, Curhan GC, Turner ST, Perinpam M, Lieske JC (2017) Polymorphisms in renal ammonia metabolism genes correlate with 24-hour urine pH. Kidney Int Rep 2(6):1111–1121PubMedPubMedCentralCrossRef

57.

Rodman JS (2002) Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology 60(3):378–382PubMedCrossRef

Titel: Empiric therapy for kidney stones
verfasst von: David S. Goldfarb
Publikationsdatum: 26.11.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Urolithiasis / Ausgabe 1/2019
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-018-1090-6

Neu im Fachgebiet Urologie

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Empiric therapy for kidney stones

Abstract

Neu im Fachgebiet Urologie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Urologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Precision medicine in renal stone-formers

Urinary proteome in inherited nephrolithiasis

Inherited proximal tubular disorders and nephrolithiasis

Empirical therapy or precision medicine for kidney stone formers in the ‘-omics’ era?

Living kidney donation from people at risk of nephrolithiasis, with a focus on the genetic forms

Molecular basis of primary hyperoxaluria: clues to innovative treatments

Neu im Fachgebiet Urologie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Urologie